Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria tetanus pertussis haemophilus influenzae type b inactivated poliovirus combined vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria tetanus pertussis Haemophilus influenzae type b inactivated poliovirus combined vaccine is a pentavalent combination vaccine developed by Shenzhen Kangtai Biological Products (Biokangtai) and its subsidiary, Beijing Minhai Biotechnology. It is designed for the active immunization of infants and children against five major infectious diseases: diphtheria, tetanus, pertussis, poliomyelitis, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). The vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens (typically pertussis toxoid and filamentous hemagglutinin), inactivated poliovirus (types 1, 2, and 3), and Hib capsular polysaccharide conjugated to a carrier protein (tetanus toxoid). It is adsorbed onto an aluminum-based adjuvant to enhance the immune response. The vaccine was approved by the National Medical Products Administration (NMPA) in China, providing a simplified immunization schedule by reducing the number of injections required compared to individual vaccines.
- Other names
- Adsorbed acellular DTP-Hib-IPV combined vaccineDTaP-IPV/Hib vaccinePentavalent vaccine (Biokangtai)Adsorbed acellular DTP-IPV-Hib pentavalent combined vaccine
02
Targets
PRNP (Cellular Prion Protein)FHA (Filamentous hemagglutinin)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)P fimbriaeTT (Tetanus toxoid)
Beyond the preview
Go deeper on adsorbed acellular diphtheria tetanus pertussis haemophilus influenzae type b inactivated poliovirus combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria tetanus pertussis haemophilus influenzae type b inactivated poliovirus combined vaccine.